Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Pharmacother ; 79: 120-8, 2016 Apr.
Article in English | MEDLINE | ID: mdl-27044820

ABSTRACT

CONTEXT: The efficacy of the combination chondroitin sulfate-glucosamine (CS-GlcN) in the treatment of knee osteoarthritis (OA) has been suggested in recent clinical studies. In vitro reports have also suggested anti-inflammatory and anti-resorptive effects of this combination. OBJECTIVE: The aim of this study was to characterize the effects of CS-GlcN on joint degradation in vivo including the assessment of inflammation and bone metabolism in a model of OA. MATERIALS AND METHODS: We have used the OA model induced by anterior cruciate ligament transection (ACLT) in ovariectomised rats. CS-GlcN was administered daily (oral gavage) from week 0 until week 12 after ovariectomy at the dose of 140 (CS)+175 (GlcN)(HCl) mg/kg. Histochemical analyses were performed, the levels of biomarkers and inflammatory mediators were measured by luminex or ELISA and bone microstructure was determined by µCT. RESULTS: CS-GlcN protected against cartilage degradation and reduced the levels of inflammatory mediators such as interleukin-1ß and tumor necrosis factor-α in the affected knee. In addition, serum biomarkers of inflammation and cartilage and bone degradation including matrix metalloproteinase-3, C-telopeptide of type II collagen and the ratio receptor activator of nuclear factor κB ligand/osteoprotegerin were significantly decreased by CS-GlcN. This treatment also tended to improve some bone microstructural parameters without reaching statistical significance. DISCUSSION AND CONCLUSIONS: These results demonstrate the chondroprotective effects of CS-GlcN in vivo, in the experimental model of ACLT in ovariectomised rats, and suggest that this combination may be useful to control the joint catabolic effects of inflammatory stress. These findings could have clinical relevance related to the prevention of joint degradation by CS-GlcN and support the potential development of OA treatments based on this combination.


Subject(s)
Anterior Cruciate Ligament Injuries/drug therapy , Anterior Cruciate Ligament/pathology , Cartilage, Articular/pathology , Chondroitin Sulfates/therapeutic use , Glucosamine/therapeutic use , Osteoarthritis, Knee/drug therapy , Protective Agents/therapeutic use , Animals , Anterior Cruciate Ligament/drug effects , Anterior Cruciate Ligament Injuries/pathology , Biomarkers/blood , Bone and Bones/drug effects , Bone and Bones/pathology , Cartilage, Articular/drug effects , Chondroitin Sulfates/pharmacology , Disease Models, Animal , Drug Therapy, Combination , Female , Glucosamine/pharmacology , Inflammation Mediators/metabolism , Joints/drug effects , Joints/pathology , Osteoarthritis, Knee/blood , Osteoarthritis, Knee/pathology , Ovariectomy , Protective Agents/pharmacology , Rats, Wistar , X-Ray Microtomography
2.
BMC Musculoskelet Disord ; 16: 92, 2015 Apr 17.
Article in English | MEDLINE | ID: mdl-25903377

ABSTRACT

BACKGROUND: Osteoarthritis (OA) is the most frequent articular disease and a leading cause of disability. There is a need for effective treatments able to slow the progression of disease. Some of the available treatments are dietary supplements providing natural components. Recent studies have shown that estrogen deficiency contributes to the pathophysiological events of OA progression. METHODS: We have used the anterior cruciate ligament transection model of OA in ovariectomised rats to study the effects of BIS076, a new formulation of a natural porcine cartilage extract associated with hydroxyapatite (as a source of calcium) and vitamin D3. Cartilage degradation, proteoglycan depletion and synovitis were followed by histochemistry. Effects on bone microstructure were determined by µCT. The levels of biomarkers in serum and inflammatory mediators in knee homogenates were measured by luminex or ELISA. RESULTS: Oral administration of BIS076 reduced articular cartilage damage and serum levels of cartilage degradation markers C-telopeptide of type II collagen and cartilage oligomeric matrix protein, as well as matrix metalloproteinase-3. The local inflammatory response was down-regulated by BIS076 with lower production of pro-inflammatory cytokines and prostaglandin E2 in joint tissues. In addition, BIS076 was effective on metaphyseal bone alterations as this formulation increased volumetric bone mineral density and improved bone micro-architecture. These effects were related to the modification of bone metabolism reflected by changes in bone biomarkers with reductions in the ratio receptor activator of nuclear factor κB ligand/osteoprotegerin and the levels of tartrate-resistant acid phosphatase-5b, suggesting an inhibitory activity of BIS076 on trabecular bone resorption. CONCLUSIONS: We have demonstrated the protective properties of a new formulation (BIS076) on joint lesion and bone alterations in an experimental model of OA in ovariectomised rats. This study supports the interest of BIS076 in OA treatments.


Subject(s)
Anterior Cruciate Ligament Injuries , Collagen Type II/therapeutic use , Glycosaminoglycans/therapeutic use , Osteoarthritis, Knee/drug therapy , Osteoarthritis, Knee/etiology , Ovariectomy/adverse effects , Tissue Extracts/therapeutic use , Animals , Biomarkers/blood , Cartilage Oligomeric Matrix Protein/blood , Collagen Type II/blood , Cytokines/blood , Dinoprostone/blood , Disease Models, Animal , Durapatite/therapeutic use , Female , Matrix Metalloproteinase 3/blood , Osteoarthritis, Knee/blood , Peptide Fragments/blood , Rats , Rats, Wistar , Swine , Treatment Outcome , Vitamin D/therapeutic use
3.
Int J Pharm ; 470(1-2): 15-27, 2014 Aug 15.
Article in English | MEDLINE | ID: mdl-24792976

ABSTRACT

As a methodology for characterizing substances with regard to its viability in direct compression, the SeDeM Diagram Expert System may be considered a new tool in terms of the number of parameters applied and its optimization. The paper is based on the experimental SeDeM characterization study of 51 directly compressible (DC) excipients. After selecting the parameters, and comparing the corresponding results, the choices available within the SeDeM Expert System could be expanded. Through applied variants, the maximum and optimal values of the DC diluent excipient were precisely defined and the mathematical limits of the parameters, functions and parametric indices that define the level of direct compressibility were established. These studies have allowed us to propose a new classification of excipients CD based on its rheological and compressibility capability, resulting in a periodic table of CD excipients. It has been determined that the best excipient for direct compression should have an index of good compression (IGC) of 8.832.


Subject(s)
Excipients/chemistry , Excipients/classification , Expert Systems , Compressive Strength , Particle Size , Porosity , Rheology
4.
Exp Gerontol ; 55: 44-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24667123

ABSTRACT

The anterior cruciate ligament transection (ACLT) model of osteoarthritis (OA) in young rats is widely used to study the pathogenesis of OA and possible treatment approaches. As aging is a key factor in the progression of this condition, it is hypothesized that animals may vary in their responses to ACLT according to their age. The histopathological features of young (2month-old) and middle-aged (12month-old) rats in the presence or absence of ACLT were compared. The results indicated that moderate degradative changes can be detected in the knee joints of sham-operated middle-aged rats compared with young animals. After ACLT, cartilage degradation was significantly higher in middle-aged rats in relation to young animals. An increase in interleukin(IL)-1ß and IL-17 suggests the presence of a local inflammatory response represented by synovitis in ACLT rats which is not dependent on age. Our study indicates that age is an important factor affecting the pathogenesis of OA changes after ACLT and it should be considered in studies using this experimental model.


Subject(s)
Aging/pathology , Anterior Cruciate Ligament Injuries , Arthritis, Experimental/etiology , Osteoarthritis/etiology , Aging/metabolism , Animals , Arthritis, Experimental/metabolism , Arthritis, Experimental/pathology , Cartilage, Articular/pathology , Collagen Type II/metabolism , Cytokines/metabolism , Disease Progression , Inflammation Mediators/metabolism , Male , Osteoarthritis/metabolism , Osteoarthritis/pathology , Proteoglycans/metabolism , Rats , Rats, Wistar , Synovitis/etiology , Synovitis/metabolism , Synovitis/pathology
5.
Regul Toxicol Pharmacol ; 62(3): 532-41, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22146797

ABSTRACT

The toxicity of a rooster comb extract (IB0004) that contains mainly sodium hyaluronate was assessed in acute and subchronic studies and in a bacterial reverse mutation assay. In a single dose acute study, male and female rats were administered 2000 mg/kg body weight (bw) of the product and observed for 14 days. No mortality was recorded, thus it was considered that the minimum lethal dose for rats by oral route was greater than 2000 mg/kg bw. A 90-day subchronic study (5, 55 and 600 mg/kg bw/day, oral gavage) with 50 male and 50 female Wistar-Hannover rats produced no significant adverse effects on food consumption, body weight, mortality, clinical biochemistry, hematology, gross pathology, and histopathology. Although some differences were observed between the treated and control animals in body weight gain (%) and some hematological parameters, these changes were generally minor in nature and, are considered to be of no toxicological significance. The no-observable-adverse-effects level was established at 600 mg/kg bw/day. There was no evidence of mutagenic activity in Salmonella typhimurium TA98, TA100, TA1535 and TA1537 or in Escherichia coli WP2 uvra pkM101. In conclusion, the results from these safety studies support the safety of rooster comb extract IB0004 in food.


Subject(s)
Comb and Wattles/chemistry , Hyaluronic Acid/isolation & purification , Hyaluronic Acid/toxicity , Toxicity Tests, Acute/methods , Toxicity Tests, Subchronic/methods , Animals , Body Weight/drug effects , Body Weight/physiology , Eating/drug effects , Eating/physiology , Female , Male , Mutagenicity Tests/methods , Random Allocation , Rats , Rats, Wistar
6.
Eur J Pharm Biopharm ; 79(2): 464-72, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21501683

ABSTRACT

As a methodology for characterizing substances in relation to their viability in direct compression, the SeDeM Diagram Expert System may be considered an open system in terms of the number of parameters applied and the optimization of these parameters. With the experience acquired from applying the SeDeM Diagram, in this study, we propose optimizing the parameters corresponding to the Hausner index (IH) and relative humidity (%HR) in order to simplify the mathematical calculation, so that it provides reliable data that can be extrapolated. The proposed optimization does not involve a conceptual change in the parameters considered nor a significant change in the results obtained compared with the previous calculation methodology initially established for the SeDeM Diagram Expert System, which means that the conclusions obtained by applying this method are equivalent.


Subject(s)
Chemistry, Pharmaceutical/methods , Drug Compounding/methods , Expert Systems , Humidity , Technology, Pharmaceutical/methods , Excipients/chemistry , Mathematical Computing , Powders/chemistry , Tablets/chemistry
7.
Eur J Pharm Biopharm ; 69(3): 1029-39, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18367387

ABSTRACT

Application of the new SeDeM Method is proposed for the study of the galenic properties of excipients in terms of the applicability of direct-compression technology. Through experimental studies of the parameters of the SeDeM Method and their subsequent mathematical treatment and graphical expression (SeDeM Diagram), six different DC diluents were analysed to determine whether they were suitable for direct compression (DC). Based on the properties of these diluents, a mathematical equation was established to identify the best DC diluent and the optimum amount to be used when defining a suitable formula for direct compression, depending on the SeDeM properties of the active pharmaceutical ingredient (API) to be used. The results obtained confirm that the SeDeM Method is an appropriate system, effective tool for determining a viable formulation for tablets prepared by direct compression, and can thus be used as the basis for the relevant pharmaceutical development.


Subject(s)
Algorithms , Chemistry, Pharmaceutical/statistics & numerical data , Drug Compounding/statistics & numerical data , Tablets , Drug Stability , Excipients , In Vitro Techniques , Lubrication , Particle Size , Powders
8.
Eur J Pharm Biopharm ; 64(3): 351-9, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16949262

ABSTRACT

The new SeDeM Method is proposed for testing the batch-to-batch reproducibility of the same active pharmaceutical ingredient (API) in powder form. The procedure describes the study of the galenic properties of substances in powder form in terms of the applicability of direct compression technology. Through experimental determination of the SeDeM Method parameters, and their subsequent mathematical treatment and graphical expression (SeDeM Diagram), three batches of the same API were analysed to determine whether it was suitable for direct compression. Batch-to-batch reproducibility of the results was verified. It was concluded that the SeDeM Method is suitable for testing batch-to-batch reproducibility of characteristics in powdered APIs substances. The results obtained confirm that the SeDeM Method is a useful, effective tool for drug-preformulation studies providing the pharmacotechnical data required when formulating a drug in tablet form. In addition, the results were effective for defining the most appropriate manufacturing technology.


Subject(s)
Chemistry, Pharmaceutical , Expert Systems , Powders , Technology, Pharmaceutical/methods , Compressive Strength , Glucosamine/chemistry , Glucosamine/standards , Models, Chemical , Quality Control , Reproducibility of Results , Tablets
SELECTION OF CITATIONS
SEARCH DETAIL
...